Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.

Diabetes, obesity & metabolism·2026

Same author

The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.

Diabetes care·2025

Same author

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.

The lancet. Diabetes & endocrinology·2025

Same author

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.

Journal of the American College of Cardiology·2024

Same author

Erratum. Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE. Diabetes Care 2024;47:556-561.

Diabetes care·2024

Same author

Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE.

Diabetes care·2024

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Glycemic control and cardiovascular mortality.

Matthew C Riddle¹

¹Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon 97239-3098, USA. riddle@ohsu.edu

Current Opinion in Endocrinology, Diabetes, and Obesity

|April 28, 2011

Summary

Treating hyperglycemia in diabetes may reduce cardiovascular risk, but benefits may be delayed. Intensive glycemic control in high-risk individuals might increase short-term mortality, necessitating further research into patient subgroups and treatment strategies.

More Related Videos

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Experiment Videos

Last Updated: Jun 2, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Area of Science:

Cardiology
Endocrinology
Public Health

Background:

Diabetes mellitus significantly elevates cardiovascular event risk.
The impact of hyperglycemia treatment on cardiovascular outcomes in diabetes remains debated.
Cardiovascular risk associated with hyperglycemia extends to levels below diabetes diagnosis.

Purpose of the Study:

To review the current evidence on the relationship between hyperglycemia treatment and cardiovascular risk in diabetes.
To explore the controversies surrounding the efficacy of glycemic control in reducing cardiovascular events.
To identify potential factors influencing the cardiovascular benefits of diabetes management.

Main Methods:

Review of epidemiologic studies and long-term follow-up data.
Analysis of existing data to identify patient subgroups.
Evaluation of outcomes from intensive glycemic treatment in high-risk populations.

Main Results:

Confirmed associations between hyperglycemia and cardiovascular risk, even at sub-diagnostic levels.
Evidence suggests cardiovascular benefits from early diabetes treatment may manifest over a decade later.
Intensive glycemic control in high-risk individuals may be associated with increased short-term mortality.

Conclusions:

Further analysis of existing data is needed to refine treatment guidelines for specific patient subgroups.
Future research should focus on early diabetes intervention with long-term follow-up and improved treatment modalities.
Personalized treatment strategies are crucial for optimizing cardiovascular outcomes in diabetic patients.